Role of antioxidants in hypertension

Journal, Indian Academy of Clinical Medicine

Volumn 12, Issue 2, 2011, Pages 122-127

  Beg, Mujahid ^a   Sharma, Vibhor ^a   Akhtar, Nishat ^a   Gupta, Ankush ^a   Mohd, Jasim ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CALCIUM CHANNEL; HOMOCYSTEINE; NITRIC OXIDE; PROTEIN; PYRIDOXINE; REACTIVE OXYGEN METABOLITE; SELENIUM; THIOL; UBIDECARENONE; URIC ACID; ZINC;

ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; DIET SUPPLEMENTATION; DIET THERAPY; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; HEART MUSCLE PERFUSION; HIGH SODIUM INTAKE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIA; KIDNEY INJURY; LEAD POISONING; LIPID PEROXIDATION; MEAN ARTERIAL PRESSURE; MICROANGIOPATHY; NONHUMAN; OXIDATIVE STRESS; PREECLAMPSIA; PROTEIN URINE LEVEL; REVIEW; VASCULAR RESISTANCE; VITAMIN BLOOD LEVEL; ZINC DEFICIENCY;

EID: 79960089778     PISSN: 09723560     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Int Med 2003; 139: 761-776.
2. Barton CH, Ni Z, Vaziri ND. Enhanced nitric oxide inactivation in aortic coarctation-induced hypertension. Kidney Int 2001; 60: 1083-1087.
3. Makino A, Skelton MM, Zou AP et al. Increased renal medullary oxidative stress produces hypertension. Hypertension 2002; 39: 667-672.
4. Zhou XJ, Vaziri ND, Wang XQ et al. Nitric oxide synthase expression in hypertension induced by inhibition of glutathione synthase. J Pharmacol Exp Ther 2002; 300: 762-767.
5. Vaziri ND, Wang XQ, Oveisi F, Rad B. Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension 2000; 36: 142-146.
6. Vaziri ND, Liang K, Ding Y. Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension. Kidney Int 1999; 56: 1492-1498.
7. Vaziri ND, Ni Z, Oviesi F et al. Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 2002; 39: 135-141.
8. Roberts CK, Vaziri ND, Wang XQ, Barnard RJ. Enhanced NO inactivation induced by a high fat, refined-carbohydrate diet. Hypertension 2000; 36: 423-429.
9. Carr A, Frei B. The role of natural antioxidants in preserving the biological activity of endothelium-derived nitric oxide. Free Radic Biol Med 2000; 28: 1806-1814.
10. Zalba G, Beaumont J, San Jose G et al. Vascular oxidant stress: molecular mechanisms and pathophysiological implications. J Physiol Biochem 2000; 56: 57-64.
11. Rathaus A, Bernheim J. Oxygen species in the microvascular environment: regulation of vascular tone and the development of hypertension. Nephrol Dial Transplant 2002; 17: 216-221.
12. Kumar KV, Das UN. Are free radicals involved in the pathobiology of human essential hypertension? Free Radic Red Commun 1993; 19: 59-66.
13. Felmeden DC, Spencer CG, Blann AD et al. Lowdensity lipoprotein subfractions and cardiovascular risk in hypertension: relationship to endothelial dysfunction and effects of treatment. Hypertension 2003; 41: 528-533.
14. Taddei S, Virdis A, Ghiadoni L et al. Endothelial dysfunction in hypertension. J Cardiovasc Pharmacol 2001; 38 (suppl 2): 11-14.
15. Amberg GC, Bonev AD, Rossow CF et al. Modulation of the molecular composition of large conductance, Ca2+ activated K+ channels in vascular smooth muscle during hypertension. J Clin Invest 2003; 112: 717-724.
16. Rodriguez-Porcel M, Lerman LO, Holmes DR et al. Chronic antioxidant supplementation attenuates nuclear factor-B activation and preserves endothelial function in hypercholesterolemic pigs. Cardiovasc Res 2002; 53: 1010-1018.
17. Hajjar IM, George V, Sasse EA, Kochar MS. A randomised, doubleblind, controlled trial of vitamin C in the management of hypertension and lipids. Am J Ther 2002; 9: 289-293.
18. Boshtam M, Rafiei M, Sadeghi K, Sarraf-Zadegan N. Vitamin E can reduce blood pressure in mild hypertensives. Int J Vitam Nutr Res 2002; 72: 309-314.
19. Carr AC, Zhu BZ, Frei B. Potential antiatherogenic mechanisms of ascorbate (vitamin C) and α-tocopherol (vitamin E). Circ Res 2000; 87: 349-354.
20. Pryor WA. Vitamin E and heart disease. Free Radic Biol Med 2000; 28: 141-164.
21. Jialal I, Fuller CJ. Effect of vitamin E, vitamin C and β-carotene on LDL oxidation and atherosclerosis. Can J Cardiol 1995.
22. Asplund K. Antioxidant vitamins in the prevention of cardiovascular disease: a systematic review. J Intern Med 2002; 251: 372-392.
23. Chen J et al. Serum antioxidant vitamins and blood pressure in the United States population. Hypertension 2002; 40: 810-6.
24. Johnson RJ et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183-1190.
25. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med 1990; 9: 515-540.
26. Parslow RA, Sachdev P, Salonikas C et al. Associations between plasma antioxidants and hypertension in a community-based sample of 415 Australians aged 60-64. Journal of Human Hypertension 2005; 19: 219-226.
27. Bello-Klein A, Bock PM, Travacio M et al. Myocardial oxidative stress and antioxidants in hypertension as a result of nitric oxide synthase inhibition. Cardiovascular Toxicology 2001; 1: 43-50.
28. Niu Tian, Kristina D Thrasher, Paul D Gundy et al. Antioxidant Treatment Prevents Renal Damage and Dysfunction and Reduces Arterial Pressure in Salt-Sensitive Hypertension. Hypertension 2005; 45: 934.
29. Roberts LJ, II, Oates JA, Fazio S et al. Alpha tocopherol supplementation reduces plasma F2-isoprostane concentrations in hypercholesterolemic humans only at doses of 800 IU or higher. Free Rad Biol Med 2002; 33 (Suppl 2): S412.
30. Duffy SJ, Gokce N, Holbrook M et al. Treatment of hypertension with ascorbic acid. Lancet 1999; 354: 2048-2049.
31. Stephens NG, Parsons A, Schofield PM et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 23 (347): 781-786.
32. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 7 (356): 1213-1218.
33. Martin Rodriguez-Porcel, Joerg Herrman, Alejandro R Chade et al. Long-term Antioxidant Intervention Improves Myocardial Microvascular Function in Experimental Hypertension. Hypertension 2004.
34. Bernardo Rodriguez-Iturbe, Chang-De Zhan, Yasmir Quiroz et al. Antioxidant-Rich Diet Relieves Hypertension and Reduces Renal Immune Infiltration in Spontaneously Hypertensive Rats. Hypertension 2003; 41: 341.
35. Vaziri ND, Liang K, Ding Y. Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension. Kidney Int 1999; 56: 1492-1498.
36. Vaziri ND, Ni Z, Oviesi F et al. Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 2002; 39: 135-141.
37. Swei A, Lacy F, De Lano FA, Schmidt-Schonbein GW. Oxidative stress in the Dahl salt-sensitive rat. Hypertension 1997; 30: 1628-1633.
38. Laursen JB, Rajagopalan S, Galis Z et al. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997; 95: 588-593.
39. Roggensack AM, Zhang Y, Davidge ST. Evidence for peroxynitrite formation in the vasculature of women with preeclampsia. Hypertension 1999; 33: 83-89.
40. Higashi Y, Sasaki S, Nakagawa K et al. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 2002; 346: 1952-1954.
41. Barton CH, Ni Z, Vaziri ND. Enhanced nitric oxide inactivation in aortic coarctation-induced hypertension. Kidney Int 2001; 60: 1083-1087.
42. Czernichow Sébastien, Bertrais Sandrine, Blacher Jacques et al. Effect of supplementation with antioxidants upon long-term risk of hypertension in the SU. VI. MAX study: association with plasma antioxidant levels. J Hypertension 2005; 23: 2013-2018.
43. Subash P, Premagurumurthy K, Sarasabharathi A, Cherian KM. Total antioxidant status and oxidative DNA damage in a South Indian population of essential hypertensives. Journal of Human Hypertension (7 January, 2010) doi:10.1038/jhh.2009.100.
44. de la Sierra A, Larrousse M. Endothelial dysfunction is associated with increased levels of biomarkers in essential hypertension. Journal of Human Hypertension (26 November 2009) doi:10.1038/ jhh.2009.9.
45. Al-Solaiman Y, Jesri A, Mountford WK et al. DASH lowers blood pressure in obese hypertensives beyond potassium, magnesium and fibre. Journal of Human Hypertension (23 July, 2009) doi:10.1038/jhh.2009.58.
46. Al-Solaiman Y, Jesri A, Zhao Y et al. Low-sodium DASH reduces oxidative stress and improves vascular function in salt-sensitive humans Low-sodium DASH and oxidative stress. Journal of Human Hypertension 209; 23: 826-835. doi:10.1038/jhh.2009.32.